211 related articles for article (PubMed ID: 8884510)
1. Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: role of dispersion of refractoriness in antiarrhythmic efficacy.
Cha Y; Wales A; Wolf P; Shahrokni S; Sawhney N; Feld GK
J Cardiovasc Electrophysiol; 1996 Sep; 7(9):809-27. PubMed ID: 8884510
[TBL] [Abstract][Full Text] [Related]
2. Electrophysiologic Effects of the New Class III Antiarrhythmic Drug Dofetilide in an Experimental Canine Model of Pacing-induced Atrial Fibrillation.
Feld GK; Cha Y
J Cardiovasc Pharmacol Ther; 1997 Jul; 2(3):195-203. PubMed ID: 10684458
[TBL] [Abstract][Full Text] [Related]
3. Dofetilide versus quinidine for atrial flutter: viva la difference!?
Olshansky B
J Cardiovasc Electrophysiol; 1996 Sep; 7(9):828-32. PubMed ID: 8884511
[TBL] [Abstract][Full Text] [Related]
4. Electrophysiologic and antiarrhythmic effects of the new class III antiarrhythmic drug KCB-328 in experimental canine atrial flutter.
Rahme MM; Ungab GA; Wadhwa M; Al-Kandari F; Yao B; Gupta A; Lee K; Kim HY; Feld GK
J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):297-306. PubMed ID: 11584336
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction.
Feld GK; Venkatesh N; Singh BN
Circulation; 1986 Jul; 74(1):197-204. PubMed ID: 3708774
[TBL] [Abstract][Full Text] [Related]
6. Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model.
Goldstein RN; Khrestian C; Carlsson L; Waldo AL
J Cardiovasc Electrophysiol; 2004 Dec; 15(12):1444-50. PubMed ID: 15610294
[TBL] [Abstract][Full Text] [Related]
7. Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug.
Crijns HJ; Van Gelder IC; Kingma JH; Dunselman PH; Gosselink AT; Lie KI
Eur Heart J; 1994 Oct; 15(10):1403-8. PubMed ID: 7821320
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of azimilide and dofetilide in the dog right atrial enlargement model of atrial flutter.
Restivo M; Hegazy M; El-Hamami M; Yin H; Caref EB; Assadi MA; Brooks RR; El-Sherif N
J Cardiovasc Electrophysiol; 2001 Sep; 12(9):1018-24. PubMed ID: 11573691
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of dofetilide, amiodarone, and class lc drugs on left and right atrial refractoriness and left atrial vulnerability in pigs.
Wirth KJ; Knobloch K
Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):166-74. PubMed ID: 11218069
[TBL] [Abstract][Full Text] [Related]
10. Effects of dofetilide on electrical dispersion and arrhythmias in post-infarcted anesthetized dogs.
D'Alonzo AJ; Sewter JC; Darbenzio RB; Hess TA
Basic Res Cardiol; 1995; 90(5):424-34. PubMed ID: 8585865
[TBL] [Abstract][Full Text] [Related]
11. Effects of azimilide dihydrochloride on circus movement atrial flutter in the canine sterile pericarditis model.
Restivo M; Hegazy M; Caref EB; Avitable MJ; Assadi MA; el-Hamami M; Yin H; Piracha M; Brooks RR; el-Sherif N
J Cardiovasc Electrophysiol; 1996 Jul; 7(7):612-24. PubMed ID: 8807407
[TBL] [Abstract][Full Text] [Related]
12. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
[TBL] [Abstract][Full Text] [Related]
13. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
McClellan KJ; Markham A
Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
[TBL] [Abstract][Full Text] [Related]
14. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
Falk RH; Pollak A; Singh SN; Friedrich T
J Am Coll Cardiol; 1997 Feb; 29(2):385-90. PubMed ID: 9014993
[TBL] [Abstract][Full Text] [Related]
15. Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap.
Inoue H; Yamashita T; Nozaki A; Sugimoto T
J Am Coll Cardiol; 1991 Oct; 18(4):1098-104. PubMed ID: 1910060
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiologic effects of SD-3212, a new class I antiarrhythmic drug, on canine atrial flutter and atrial action-potential characteristics.
Fujiki A; Tani M; Hayashi H; Mizumaki K; Inoue H; Uemura H; Nakaya H
J Cardiovasc Pharmacol; 1997 Apr; 29(4):471-5. PubMed ID: 9156356
[TBL] [Abstract][Full Text] [Related]
17. Dofetilide effects on the inhibition by trains of subthreshold conditioning stimuli.
Chorro FJ; Sanchis J
Pacing Clin Electrophysiol; 2004 Mar; 27(3):327-32. PubMed ID: 15009858
[TBL] [Abstract][Full Text] [Related]
18. Dofetilide, a new class III antiarrhythmic agent, reduces pacing induced heterogeneity of repolarisation in vivo.
Gwilt M; King RC; Milne AA; Solca AM
Cardiovasc Res; 1992 Nov; 26(11):1102-8. PubMed ID: 1291088
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of double potentials recorded during sustained atrial flutter in the canine right atrial crush-injury model.
Feld GK; Shahandeh-Rad F
Circulation; 1992 Aug; 86(2):628-41. PubMed ID: 1638727
[TBL] [Abstract][Full Text] [Related]
20. Dofetilide: a new pure class III antiarrhythmic agent.
Falk RH; Decara JM
Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
